Quantify leads with most Findata permits issued in 2024 for an RWE provider!
Findata β Finnish Social and Health Data Permit Authority has published its annual review of 2024. Here are some highlights:
π’ In 2024, Findata turned 5 [β¦]
Findata β Finnish Social and Health Data Permit Authority has published its annual review of 2024. Here are some highlights:
π’ In 2024, Findata turned 5 [β¦]
Here are some of the things that makes our data unique:
1οΈβ£Fast access to comprehensive data
The average time to fully process applications at The Danish Health Data Authority ( [β¦]
Certain patient groups may be underrepresented or excluded from RCTs due to eligibility criteria, logistical barriers, ethical concerns or other reasons.
Examples of these potential groups are females, pregnant or breastfeeding females, older adults due to age or comorbidities, children, people [β¦]
Quantify Researchβs very own Mary Rosenzweig will join speakers from Monsenso, Lundbeck and [β¦]
Real-world evidence derived from data collected in routine clinical care is increasingly important for decision-makers in payer and regulatory environments.
Nordic health data has several characteristics that enable a globally unique research environment [β¦]
As the number one provider of Nordic registry studies, Quantify sits at the heart of Scandinavia.
The Nordics typically refers to Northern European countries with similar history, culture and social structures.
They include Denmark, [β¦]
Data thatβs not fit-for-purpose can be scary, but hereβs the good news β Nordic data has many characteristics that allow it to be considered high-quality for a wide range of purposes. These [β¦]
The landscape of healthcare research is rapidly evolving, and social media is emerging as a valuable resource for real-world evidence (RWE) studies.
In one of Quantifyβs publications, ππ¨ππ’ππ₯ ππππ’π ππ’π¬πππ§π’π§π ππ¨π« ππππ₯-ππ¨π«π₯π ππ―π’πππ§ππ: π ππ¨π―ππ₯ ππ©π©π«π¨πππ‘ ππ¨ ππππ«π’π§π ππ‘π ππππ’ππ§πβπ¬ ππ¨π’ππ, [β¦]
Literature reviews are essential throughout the pharmaceutical product development lifecycle, from identifying therapeutic targets to assisting with regulatory and health technology assessment submissions and ultimately improving drug safety and patient outcomes at every stage.
This image presents the use cases for [β¦]
Nordic registers have been described as a goldmine for producing Real-World Evidence (RWE) in health and welfare research.
The benefits of national registers are well-known; these administrative registers provide comprehensive longitudinal individual-level data with complete coverage for the total population.
Today, weβd [β¦]